Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adalgisa Condoluci

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Annals of Hematology|July 17, 2024
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expressionMax J Rieger, Thomas Pabst, Barbara Jeker, et al.
Blood|February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trialAdalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
Frontiers in Oncology|April 4, 2025
The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatmentVanessa Cristaldi, Lodovico Terzi di Bergamo, Lucrezia Patruno, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 11, 2023
Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosisFrancesco Marchi, Chiara Kessler, Daniela Distefano, et al.
Journal of Thrombosis and Haemostasis : JTH|June 8, 2021
The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccinationMicol G Cittone, Raphael Battegay, Adalgisa Condoluci, et al.
Blood Advances|September 9, 2021
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumabAlessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, et al.
Hematological Oncology|June 3, 2022
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinibAdalgisa Condoluci, Lisa Milan, Gabriela Forestieri, et al.
The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.
Frontiers in Oncology|August 19, 2021
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic LeukemiaFortunato Morabito, Giovanni Tripepi, Riccardo Moia, et al.
Haematologica|July 29, 2017
Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemiaPietro Bulian, Riccardo Bomben, Michele Dal Bo, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Annals of Hematology|July 17, 2024
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expressionMax J Rieger, Thomas Pabst, Barbara Jeker, et al.
Blood|February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trialAdalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
Frontiers in Oncology|April 4, 2025
The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatmentVanessa Cristaldi, Lodovico Terzi di Bergamo, Lucrezia Patruno, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 11, 2023
Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosisFrancesco Marchi, Chiara Kessler, Daniela Distefano, et al.
Journal of Thrombosis and Haemostasis : JTH|June 8, 2021
The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccinationMicol G Cittone, Raphael Battegay, Adalgisa Condoluci, et al.
Blood Advances|September 9, 2021
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumabAlessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, et al.
Hematological Oncology|June 3, 2022
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinibAdalgisa Condoluci, Lisa Milan, Gabriela Forestieri, et al.
The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.
Frontiers in Oncology|August 19, 2021
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic LeukemiaFortunato Morabito, Giovanni Tripepi, Riccardo Moia, et al.
Haematologica|July 29, 2017
Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemiaPietro Bulian, Riccardo Bomben, Michele Dal Bo, et al.
Pageof 5